Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Slides:

Advertisements

Similar presentations

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Advertisements

Enhanced DNA damage in IDH1 mutant glioma cells.

DNA damage foci in irradiated cells.

Fig. 1. TP is highly expressed in myeloma.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

DNA-damage (γ-H2AX) and telomere damage–induced foci (TIFs).

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Bay induced aggregation of Cp occurs in HBV-infected HepG2-NTCP cells.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Analysis of brain and spinal cord of treated Gaa−/− mice and controls

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 3. BET inhibition reduces homologous recombination.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 3. A circadian rhythm in fibroblast wound-healing response.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.

Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.

Fig. 4. MATE1 transcription in RCC.

Fig. 4. Expression of HGF in liver ECs cooperates with NOX4 inhibition to enhance engraftment of regenerative hepatocytes. Expression of HGF in liver ECs.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Workflow of a sample-to-answer AST performed in less than 30 min

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 1. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like pathology in cultured rat myocytes that is abrogated by arimoclomol.

Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 3 CSF1 is expressed in human melanoma.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 2. Spontaneous inflammasome activation by pyrin S242R.

Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.

Fig. 3. BET inhibition reduces homologous recombination.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

Combined inhibition of Wee1 and PARP causes persistent radiation-induced DNA damage. Combined inhibition of Wee1 and PARP causes persistent radiation-induced.

Microfluidic platform for cell phenotype and gene function analysis

Γ-H2AX foci formation in ATM−/− and DNA-dependent protein kinase catalytic subunit (DNA-PKcs)−/− mouse embryo fibroblasts (MEFs) but not in ATM−/− MEFs.

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 7. JQ1 represses the enhancer-promoter interaction of BRCA1.

Presentation transcript:

Fig. 2. BET inhibition enhances PARPi-induced DNA damage. BET inhibition enhances PARPi-induced DNA damage. (A) DNA damage in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib, measured by the comet assay. Scale bars, 10 μm. (B) Extent of DNA damage, quantified by the tail moment in the comet assay. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Bars represent mean values of tail moment. (C) Representative images of γH2AX foci in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. Scale bars, 10 μm. DAPI, 4′,6-diamidino-2-phenylindole. (D) Quantification of the number of γH2AX-positive foci in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. (E) Western blot analysis of γH2AX in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. Lu Yang et al., Sci Transl Med 2017;9:eaal1645 Published by AAAS